Health Canada has stated that its approval of a widely used herbicide will not be impacted by the withdrawal of a crucial research paper. The study, conducted 25 years ago, concluded that glyphosate, the main component in Roundup, is safe for human use. However, the journal Regulatory Toxicology and Pharmacology recently retracted the paper, citing information revealed in U.S. litigation.
The retraction raised concerns as the study served as a foundational reference for many regulatory decisions regarding the safety of glyphosate. Allegations emerged that employees of Monsanto, the manufacturer of Roundup, potentially played a role in drafting the paper without proper recognition, a practice known as ghostwriting. There were also suggestions that Monsanto may have financially influenced the study authors. Consequently, the retraction highlighted that the paper’s conclusions on glyphosate’s carcinogenic properties were primarily based on unpublished studies from Monsanto.
Despite this development, Health Canada emphasized that their previous review conclusions remain unaffected by the retraction. The department conducted an independent evaluation of the primary data sources used in the retracted paper. Health Canada’s re-evaluation of glyphosate involved over 1,300 studies, including industry-supplied research and data from other regulatory bodies.
Calls for Health Canada to conduct a special review of glyphosate have been amplified following the retraction. The herbicide, extensively used in Canada on crops like canola and wheat, has faced increasing scrutiny due to potential health and environmental concerns. Glyphosate sales in Canada exceed 50 million kilograms annually, making it the most prevalent pesticide in the country and globally.
In response to the ongoing debate, Bayer reiterated its support for the safety of glyphosate-based products, emphasizing regulatory endorsements from health authorities worldwide, including Health Canada. Meanwhile, Monsanto maintained that its involvement in the retracted paper did not amount to authorship and that the study authors retained full control over the manuscript.
The retraction has reignited the discussion on glyphosate’s safety, with experts urging thorough reviews of the latest scientific findings to ensure public health and environmental protection. Despite varying perspectives on glyphosate’s carcinogenic potential, the retraction serves as a reminder of the importance of continually reassessing the safety of widely used chemicals.